Search

Displaying results 9841 - 9850 of 10000 in total
  1. Drug

    GS030-DP

    go.drugbank.com/drugs/DB17847
    Investigational

    GS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa.

  2. Drug

    AC-003

    go.drugbank.com/drugs/DB22691
    Investigational

    [L53458] It is being investigated for the treatment of acute graft-versus-host disease (GVHD) and idiopathic pulmonary fibrosis (IPF).[L53458] … AC-003 is a selective, oral small-molecule inhibitor of receptor-interacting protein kinase 1 (RIPK1).

  3. Drug

    NGN-401

    go.drugbank.com/drugs/DB18594
    Investigational

    Developed by Neurogene Inc., it is being investigated for the treatment of Rett syndrome.

  4. Drug

    CP-39,332

    go.drugbank.com/drugs/DB09193
    Experimental

    However, none of the members of this stereoisomers has been marketed.

  5. Drug

    Cimetropium

    go.drugbank.com/drugs/DB09271
    Investigational

    It has never been approved for use in the U.S. or Canada.

  6. Drug

    Drostanolone propionate

    go.drugbank.com/drugs/DB14655
    ApprovedIllicit

  7. Drug

    BW-A 58C

    go.drugbank.com/drugs/DB06740
    Experimental

    BW-A 58C, also known as 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone, is an experimental naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy

    Synonyms: 2-(4'-t-Butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone
  8. Drug

    Taspoglutide

    go.drugbank.com/drugs/DB14027
    Investigational

    In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects. As of May 2013 no new trials had been registered.

  9. Drug

    BNT162a1 SARS-CoV-2 Vaccine

    go.drugbank.com/drugs/DB15697
    Experimental

    [L15002, L15007] BNT162a1 is undergoing evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701).[L15017, L15022]

  10. Drug

    BNT162c2 SARS-CoV-2 Vaccine

    go.drugbank.com/drugs/DB15698
    Experimental

    [L15002, L15007] BNT162c2 is undergoing evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701).[L15017, L15022]